Publications by authors named "Patricia Coyle"

Claim this Profile
I
Impact of sex on multiple sclerosis therapy.
Patricia K Coyle

Neurotherapeutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special Edition: Therapeutic advances in multiple sclerosis.
Patricia K Coyle

Neurotherapeutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
Carson M Quinn, Prashanth Rajarajan, Alexander J Gill, Hannah Kopinsky, Andrew B Wolf, Patricia Coyle

Neurology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Do I Approach the Evaluation and Treatment of Early Lyme Disease?
Steven E Schutzer, Patricia K Coyle

NEJM Evid· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.
Roham Hadidchi, Stephen H Wang, David Rezko, Sonya Henry, Patricia K Coyle

Mult Scler Relat Disord· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn

Neurol Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
Patricia K Coyle, Mark S Freedman, Bruce A Cohen, Bruce A C Cree, Clyde E Markowitz

Ann Clin Transl Neurol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Dejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, Andrew D Goodman, Malcolm Gottesman

J Neurol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
Dejan Jakimovski, Katelyn S Kavak, Karen Zakalik, Corey McGraw, Malcolm Gottesman, Patricia K Coyle

J Neurol Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Patricia K Coyle, Magdaliz Gorritz, Rolin L Wade, Zifan Zhou, Subhan Khalid

Mult Scler Relat Disord· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
Amy D De Lury, Joseph A Bisulca, Jimmy S Lee, Muhammad D Altaf, Patricia K Coyle

J Neurol Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.
Hayrettin Tumani, Patricia K Coyle, Claudia Cárcamo, Cinzia Cordioli, Pablo A López

Mult Scler J Exp Transl Clin· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Le H Hua, Amit Bar-Or, Stanley L Cohan, Fred D Lublin, Patricia K Coyle

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
Dejan Jakimovski, Katelyn S Kavak, Karen Zakalik, Timothy Coetzee, Malcolm Gottesman, Patricia K Coyle

Mult Scler· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist, Patricia K Coyle

Neurodegener Dis Manag· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Léorah Freeman, Erin E Longbrake, Patricia K Coyle, Barry Hendin, Timothy Vollmer

CNS Drugs· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
Patricia K Coyle, Olga Syritsyna

Mult Scler· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Gavin Giovannoni, Patricia K Coyle, Patrick Vermersch, Bryan Walker, Julie Aldridge

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas Leist, Patricia K Coyle

Mult Scler· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Patricia K Coyle, Anne Gocke, Megan Vignos, Scott D Newsome

Adv Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Dejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, Andrew D Goodman, Patricia K Coyle

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Can We Learn from Sex Differences in MS?
Patricia K Coyle

J Pers Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Patricia K Coyle, Anne Gocke, Megan Vignos, Scott D Newsome

Adv Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4 T Cells.
Xun Lin, Suzanne Tawch, Hoi Tong Wong, Suyasha Roy, Stephen Gaudino, Patricia Coyle

J Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Mark S Freedman, Patricia K Coyle, Giancarlo Comi, Susan L Scarberry, Doris Damian

Mult Scler J Exp Transl Clin· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis